Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

44.4%

4 terminated/withdrawn out of 9 trials

Success Rate

55.6%

-31.0% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

100%

5 of 5 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 1

6(66.7%)

Phase 2

2(22.2%)

Phase 3

1(11.1%)

9Total

Phase 1(6)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04808622Phase 1Completed

Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxygen Levels in Healthy Volunteers

Role: lead

NCT05079126Phase 2Terminated

Study of Trans Sodium Crocetinate in Patients With Interstitial Lung Disease

Role: lead

NCT04573322Phase 1Completed

Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects

Role: lead

NCT05036980Phase 1Completed

Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Trans Sodium Crocetinate in Healthy Volunteers Exercising at Altitude

Role: lead

NCT03393000Phase 3Terminated

Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Role: lead

NCT03763929Phase 2Terminated

Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke

Role: lead

NCT01465347Phase 1Completed

Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma

Role: lead

NCT00725881Phase 1Completed

Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication

Role: lead

NCT00826930Phase 1Terminated

Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma

Role: lead

All 9 trials loaded